Concerning obesity, ADMSCs have shown their potential activity treating atherosclerosis, since they reveal pro-angiogenic and anti-atherosclerotic activities, including endothelial cell growth enhancement and survival, through modulating vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and IGF-1 levels. Here, VEGFA is linked to obesity due to melanocortin 4 receptor deficiency.